Company news

Santen Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Santen Announces Change of Major Shareholder

October 26, 2026

Notice Regarding the Petition for Commencement of Bankruptcy Proceedings of a Consolidated Subsidiary

October 16, 2026

Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

September 30, 2026

New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia

September 14, 2026

Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

September 3, 2026

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)

August 6, 2026

Santen Pharmaceutical: China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland

April 16, 2026

Notice of Board of Director and Corporate Auditor Nominations

March 19, 2026

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

January 8, 2026

Santen Pharmaceutical Launches Verkazia® (Ciclosporin Eye Drops (III)) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults

December 23, 2025

Santen Pharmaceutical Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis

December 22, 2025

Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List

December 5, 2025

Santen Pharmaceutical and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases

December 3, 2025

On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”

November 20, 2025

Santen Pharmaceutical Announces Completion of Share Buyback

November 6, 2025

Santen Pharmaceutical Announces Cancellation of Treasury Shares

November 6, 2025

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2025 (IFRS)

November 6, 2025

Santen Pharmaceutical Announces Status of Share Buyback

November 4, 2025

Santen Pharmaceutical Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension

October 22, 2025

Santen Pharmaceutical: Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea

October 19, 2025

Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”

October 16, 2025

Koya Medical Honored by Goldman Sachs for Entrepreneurship

October 15, 2025

Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

October 1, 2025

Santen Pharmaceutical and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China

September 30, 2025

Santen Pharmaceutical Publishes its Annual Integrated Report “ Report 2025”

September 25, 2025

Santen Pharmaceutical Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension

August 31, 2025

Santen Pharmaceutical Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension

August 25, 2025

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

August 18, 2025

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025 (IFRS)

August 7, 2025

Decks

The 5 newest of 46 decks. Every deck is listed under its year.